Australia News

Found 6,416 articles

• Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

  2/18/2019

  Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) from sophisticated and institutional investors that will result in 12,857,143 fully paid ordinary shares being issued at AUD$0.14 per share (Placement).

• Further Data Analysis of Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate

  2/18/2019

  Bionomics Limited announces that an additional data analysis conducted in Sweden by Pharmetheus AB showed a statistically significant response when drug exposure versus response was measured in the Phase 2 PTSD Trial.

• 

  WHO Plans to Develop Oversight Standards for Gene Editing Following Chinese Researcher’s Experiment

  2/15/2019

  Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action.

• Minomic Signs Agreement with US Pathology Laboratory

  2/14/2019

  Minomic International Ltd is pleased to announce the company has executed an agreement with Cirrus Dx, a CLIA Certified “High Complexity” Laboratory, enabling US clinicians and patients early access to the company’s novel test for Prostate Cancer.

• GI Dynamics Announces Institutional Review Board Approval for EndoBarrier Pivotal Trial

  2/14/2019

  GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has received Institutional Review Board approval to conduct its pivotal trial of EndoBarrier for type 2 diabetes and obesity.

• Mayne Pharma launches Lexette (TM) (halobetasol propionate) foam 0.05% in the United States

  2/13/2019

  Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of LEXETTE™ (halobetasol propionate) Foam 0.05% in the United States.

• Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

  2/13/2019

  Cartherics Pty Ltd and panCELLa Inc. are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.

• Appointment of Executive Director, Dr Michael Thurn

  2/12/2019

  Philadelphia PA and Sydney Australia, 12 February 2019: Medical dermatology company Botanix Pharmaceuticals Limited is pleased to announce the appointment of Dr Michael Thurn, Head of Australian Operations, as Executive Director.

• SpeeDx Develops Multiplex Test for Respiratory Viruses

  2/12/2019

  New molecular assay, PlexPCR RespiVirus, submitted to TGA for clinical approval

• Cellmid: Significant New Findings Published on Midkine

  2/7/2019

  Cellmid Limited (ASX: CDY) is pleased to advise that the prestigious Journal of Experimental Medicine has published a highly significant study showing for the first time that midkine, around which the Company holds extensive intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis

• The iQ Group Global Introduces the Saliva Glucose Biosensor

  1/31/2019

  The iQ Group Global, a consortium of life science and financial services companies which span the biopharma value chain from asset discovery to commercialization, today introduced the Saliva Glucose Biosensor.

• Avita Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update

  1/31/2019

  Pre-launch U.S. product sales of A$1.1 million in second quarter

• TOLSURA (TM) (SUBA®-itraconazole) Antifungal Capsule Now Available in the United States

  1/30/2019

  Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of TOLSURA™ (SUBA®-itraconazole) 65mg capsule in the United States.

• Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference

  1/29/2019

  Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that its Chief Executive Officer, James Nathanielsz, will be presenting at the 2019 BIO CEO & Investor Conference on Tuesday, F

• AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

  1/28/2019

  RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019

• 

  January 25 Research Roundup: Alzheimer’s Memory Recovery and Testing, New Antibiotics, Possible S...

  1/25/2019

  There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

• Arista Cereal Technologies Announces Dismissal of Patent Dispute With Arcadia Biosciences Over High Fiber Wheat

  1/24/2019

  Arista Cereal Technologies Pty Ltd (ARISTA) announces that the lawsuit initiated by Arcadia Biosciences Inc. against ARISTA in the District Court for the Southern District of New York (SDNY) has been dismissed.

• George Clinical announces the appointment of James Cheong to the role of Chief Operating Officer

  1/22/2019

  George Clinical, headquartered in Sydney, Australia, a global scientifically backed CRO, today announced the appointment of James Cheong to the role of Chief Operating Officer.

• New Device that can Rapidly Diagnose Disease Could Save Lives

  1/21/2019

  Monash University biospectroscopists have been issued a US patent for the diagnostic technology they hope will one day help doctors to diagnose and treat patients much faster than current pathology methods.

• Propanc Biopharma Commences Drug Discovery Research Collaboration

  1/2/2019

  University of Jaén to Co-fund 3 to 4 Year Program, Appoints Scientist to Lead Research Activities